IL-13 R alpha 2

IL-13 R alpha 2

IL-13 R alpha 2 Overview

Molecule Name
Interleukin-13 receptor subunit alpha-2
Synonyms
IL13RA2,CD213A2,CT19,IL-13R,IL13BP
Drug Development Progress
Drugs in Clinical Trials9
Approved Drugs0
Highest Development StagePhase 1 Clinical
Target Synonym
Interleukin 13 Receptor Alpha 2 Chain,Interleukin-13 Receptor alpha2 Subunit,IL-13RA2,IL-13R-alpha-2,Interleukin-13-binding protein,IL13RA2,Interleukin 13 Receptor Subunit Alpha 2,Interleukin 13 Receptor, Alpha 2,IL-13 Receptor Subunit Alpha-2,Cancer/Testis Antigen 19,IL-13R Subunit Alpha-2,Interleukin-13 Receptor Subunit Alpha-2,Interleukin 13 Binding Protein,CD213a2 Antigen,CD213A2,IL-13R,IL13BP,IL13R,CT19
Background
Interleukin-13 receptor subunit alpha-2 is also known as IL13Rα2, IL13Ra2 cluster of differentiation 213A2, CD213A2, CT19, IL-13R, IL13BP, and is a membrane bound protein that in humans is encoded by the IL13RA2 gene. IL13Rα2 is closely related to IL13Rα1, a subunit of the interleukin-13 receptor complex. This protein binds IL13 with high affinity, but lacks any significant cytoplasmic domain, and does not appear to function as a signal mediator. It is, however able to regulate the effects of both IL13 and IL4, despite the fact it is unable to bind directly to the latter. It is also reported to play a role in the internalization of IL13. IL13Rα2 is a component of the cell surface receptors, however, the majority exists in intracellular pools and in soluble form, and thus plays an opposite role as a potent IL13 antagonist compared with IL13Rα1. It also functions as an inhibitor of IL4-dependent pathway probably through the physical interaction between the short intracellular domain of and cytoplasmic domain of IL13Rα2 and the IL4Rα chain. In spite of the failed STAT signaling function, IL13Rα2 dose induce TGF-beta production and fibrosis. Additionally, IL13Rα2has been reported to be abundantly and specifically overexpressed in glioblastoma multiforme.

IL-13 R alpha 2 Product List

No Data
You Have Viewed 0 Of 0 Results
  • 1

Can’t find what you need?

Submit your requirements and our technical
team will help.

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
MB-101 (Mustang Bio)MB-101Phase 1 ClinicalCity Of Hope National Medical Center, Mustang Bio Inc
Brain Neoplasms; CNS Embryonal Tumor; Glioblastoma; Glioma
Details
IL13Ralpha2 CAR-T cell therapy (Jonsson Comprehensive Cancer Center)Phase 1 ClinicalUclas Jonsson Comprehensive Cancer Center
Adenocarcinoma of Lung; Adenoma, Islet Cell; Adrenocortical Carcinoma; Breast Neoplasms; Ependymoma; Glioblastoma; Medulloblastoma; Melanoma; Neuroendocrine Tumors; Paraganglioma; Pheochromocytoma; Skin Melanoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Thyroid Neoplasms; Uveal melanoma
Details
E-Sync T Cell Therapy (University of California/National Cancer Institute/California Institute for Regenerative Medicine)Phase 1 ClinicalUniversity Of California San Francisco
Glioblastoma
Details
EPC-003EPC-003Phase 1 ClinicalElpis BioPharmaceuticals Corp
Glioblastoma; Multiple Myeloma
Details
IL13Rα2 CAR-T Cells Secreting Anti-PD-L1 Antibody therapy (Emergency General Hospital)Phase 1 ClinicalEmergency General Hospital, Department of Neurosurgery
Glioma
Details
IL13Rα2 targeted CAR-T cell(Yooyoung)YYB-103; CLM-103Phase 1 ClinicalYooYoung Pharmaceutical Co Ltd
Amyotrophic Lateral Sclerosis; Glioma
Details
Autologous TGF-betaR2KO/IL13R-alpha2-CAR T cells Therapy(City of Hope Medical Center)Phase 1 ClinicalCity Of Hope National Medical Center
Astrocytoma; Glioblastoma
Details
MT-026MT-026Phase 1 ClinicalT-Maximum Pharmaceutical (Suzhou) Co Ltd
Glioma
Details
SNC-109SNC109; SNC-109Phase 1 ClinicalShanghai Simnova Biotechnology Co Ltd
Glioblastoma
Details